Abstract Background New oral anticoagulants (NOACs) offer an alternative to warfarin for
preventing stroke in patients with atrial fibrillation. NOACs are expected to replace warfarin …

In recent years, non-vitamin K oral anticoagulants (NOACs) have emerged as an alternative
to warfarin for the prevention and treatment of thrombo-embolic disease. Large randomized …

Background: Evidence is conflicting as to the efficacy of direct oral anticoagulation (DOAC)
and vitamin K antagonist (VKA) for prevention of myocardial infarction (MI). Objectives: This …

Novel oral anticoagulants (NOACs) that directly inhibit thrombin (dabigatran) or factor Xa
(rivaroxaban, apixaban, edoxaban) are effective therapies for the prevention and treatment …

Objective The efficacy of add-on use of spironolactone in patients with resistant
hypertension has been investigated in several small studies. We performed this meta …

Background and Objectives There are limited data on the use of non-vitamin K antagonist
oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with cancer. We aimed to …

In patients with AF, adjusted-dose warfarin and antiplatelet agents reduce the risk for stroke
by≈ 65% and by≈ 20%, respectively. 17 However, oral antiplatelet agents do not perform …

Background Assessing and improving patients' anticoagulation knowledge can lead to
better treatment outcomes. While validated knowledge instruments exist for use in people …

Background and Purpose—Specific coagulation assays for non–vitamin K antagonist oral
anticoagulants (NOAC) are relatively slow and often lack availability. Although specific point …

Each year, 1· 0–2· 0% of individuals with atrial fibrillation and 0· 1–0· 2% of those with
venous thromboembolism who are receiving one of the novel oral anticoagulants …